- INGREZZA® (valbenazine) demonstrated significant improvements in functional and health-related quality of life for tardive dyskinesia patients.
- The Phase 4 study showed continued benefits in mobility and anxiety/depression with prolonged INGREZZA treatment.
- Significant functional improvements were reported in work, social, and family life metrics.
Neurocrine Biosciences (NBIX, Financial) presented new findings at the 2025 ISPOR Conference from a Phase 4 study on INGREZZA® (valbenazine), which highlight substantial improvements in the quality of life for patients with tardive dyskinesia. The study involved 127 patients who initially received up to 80 mg of INGREZZA for 8 weeks, followed by randomization to either continue INGREZZA (n=59) or receive a placebo (n=59) for an additional 8 weeks.
Patients treated with INGREZZA scored significant improvements in multiple health-related quality of life measures. The findings include advancements in mobility (-0.27), self-care (-0.28), usual activities (-0.36), and pain/discomfort (-0.34). Continued treatment with INGREZZA further improved mobility and anxiety/depression scores, outperforming placebo results.
Functionally, the study reported significant improvements across various domains, such as work/school (-1.37), social life (-1.65), family/home life (-1.30), and an overall reduction in the SDS total score (-4.28). Patients continuing on INGREZZA showed additional benefits in social and family life compared to placebo.
These findings underscore INGREZZA's effectiveness in addressing both functional impairments and improving the quality of life in patients with tardive dyskinesia, enhancing its clinical profile and reinforcing its position in treatment guidelines.
